Skip to main content

Table 1 Baseline demographic and clinical characteristics of enrolled patients with mCRC

From: Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Characteristic No. of patients [cases (%)]
Sex
 Male 27 (67.5)
 Female 13 (32.5)
ECOG PS
 0 15 (37.5)
 1 25 (62.5)
Primary disease site
 Colon 23 (57.5)
 Rectosigmoid colon 1 (2.5)
 Rectum 16 (40.0)
Primary tumor resection
 No 7 (17.5)
 Yes 33 (82.5)
Adjuvant chemotherapy
 No 24 (60.0)
 Yes 16 (40.0)
Differentiation
 Well 1 (2.5)
 Moderate 29 (72.5)
 Poor 3 (7.5)
 Unknown 7 (17.5)
Metastatic sites
 Liver 24 (60.0)
 Lung 16 (40.0)
 Lymph nodes 10 (25.0)
 Peritoneum 8 (20.0)
 Others 4 (10.0)
No. of metastatic sites
 1 14 (35.0)
 2 18 (45.0)
 ≥3 8 (20.0)
  1. mCRC metastatic colorectal cancer, ECOG Eastern Cooperative Oncology Group, PS performance status